Eptifibatide (brand name Integrilin) acts as a glycoprotein IIb/IIIa receptor antagonist and is used in interventional neuroradiology for thromboembolic events. The effect of eptifibatide is based on inhibition of platelet aggregation, and it has a plasma elimination half-life of approximately 2.5 hours.